Pharmaceutical composite formulation comprising metformin, linagliptin and meglumine
A pharmaceutical formulation with meglumine as a stabilizer in the drug coating layer and an acidic stabilizer in the core part addresses stability issues and NDMA formation in linagliptin-metformin combinations, enhancing the stability and safety of the drug product.
Patent Information
- Application Number
- KR1020210139537
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-10-19
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2041-10-19
AI Technical Summary
The stability of combination drug products containing linagliptin and metformin is compromised due to their interaction, leading to the formation of related substances, and there is a risk of generating harmful N-nitrosodimethylamine (NDMA) when metformin is present in a higher pH environment.
A pharmaceutical formulation is developed with a drug coating layer containing meglumine as a basic stabilizer and an inner coating layer between the core containing metformin and the drug coating layer, along with an acidic stabilizer in the core part to maintain a low pH, ensuring stability and preventing NDMA formation.
The formulation achieves enhanced stability of linagliptin and reduces NDMA formation, maintaining the integrity and safety of the drug product.
Smart Images

Figure 112021119714853-PAT00002_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a pharmaceutical complex formulation comprising metformin, linagliptin, and meglumine, and more specifically, to a pharmaceutical complex formulation in which a drug coating layer containing linagliptin comprises meglumine, a sugar alcohol having an amine group, as a basic stabilizer, and an endothelial coating layer is formed between a core part containing metformin and a drug coating layer. Background Technology
[0002] Linagliptin is the generic name for 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl-1H-purine-2,6-dione, and has the following molecular structural formula.
[0003]
[0004] The above-mentioned linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor and is widely used for the treatment of diabetes in combination with specific partner drugs such as metformin hydrochloride (Metformin HCl).
[0005] The above DPP-4 is an enzyme also known as CD26, which is a serine protease that causes the separation of a dipeptide from the N-terminus in many proteins having a proline or alanine residue at the N-terminus. Due to these characteristics, DPP-4 inhibitors are considered promising drugs for the treatment of diabetes because they interfere with the plasma levels of bioactive peptides, including the peptide GLP-1.
[0006] Sitagliptin or vildagliptin are known as DPP-4 inhibitors. The above-mentioned sitagliptin (MK-0431) is a commonly used DPP-4 inhibitor, and (3R)-3-amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-5H[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one ((3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-5H[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one) or It is named (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine. In one embodiment, sitagliptin is in the form of its dihydrogen phosphate salt, namely sitagliptin phosphate. In additional embodiments, the sitagliptin phosphate is in the form of a crystalline anhydride or monohydrate. This form is referred to as sitagliptin phosphate monohydrate.
[0007] In addition, the above-mentioned vildagliptin is specifically disclosed in U.S. Patent No. 6,166,063, etc. A specific salt of the above-mentioned vildagliptin is disclosed in International Publication No. WO2007 / 019255. A crystalline form of the above-mentioned vildagliptin is disclosed in International Publication No. WO2006 / 078593.
[0008] Partner drugs used in combination with the DPP-4 inhibitor described above as a pharmaceutical composition include biguanides (e.g., metformin), thiazolidinediones (e.g., pioglitazone), statins (e.g., atorvastatin), or ARBs (e.g., telmisartan).
[0009] Combination drugs containing DPP-4 inhibitors and their partner drugs are already widely used clinically. A representative example is Trajenta DUO, which contains linagliptin and metformin. ® There is. The above-mentioned Trajenta DUO has a therapeutic effect by simultaneously administering linaglitib, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, its partner drug.
[0010] However, when manufacturing combination preparations containing two or more active ingredients, such as linagliptin and metformin, problems with the stability of the active ingredients may arise due to interactions between two or more different active ingredients. In particular, since linagliptin reacts with metformin to form a related substance, there is a problem that the stability of the combination preparation may be reduced. Prior art literature
[0011] Republic of Korea Registered Patent No. 10-1111101 The problem to be solved
[0012] The technical problem that the present invention aims to solve is to provide a pharmaceutical compound formulation in which the stability of the drug coating layer is ensured by including meglumine, a sugar alcohol having an amine group, as a basic stabilizer in the drug coating layer containing linagliptin, and providing an inner coating layer between the core part containing metformin and the drug coating layer.
[0013] In addition, the technical problem that the present invention aims to solve is to provide a pharmaceutical complex formulation in which N-nitrosodimethylamine (NDMA) stability is ensured by including an acidic stabilizer of an organic acid in the core part containing metformin so as to form a low pH environment.
[0014] The problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art from the description below. means of solving the problem
[0015] To solve the above problem, according to one aspect of the present invention, a pharmaceutical compound formulation is provided comprising: a core portion comprising metformin, a pharmaceutically acceptable salt thereof, or a hydrate thereof; an endothelial coating layer formed on the core portion; and a drug coating layer formed on the endothelial coating layer comprising linagliptin, a pharmaceutically acceptable salt thereof, or a hydrate thereof and meglumine.
[0016] Here, the core portion comprises 500 to 1,000 mg of the metformin, a pharmaceutically acceptable salt thereof, or a hydrate thereof, and the drug coating layer may comprise 2.5 to 5.0 mg of the linagliptin, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
[0017] At this time, the drug coating layer may contain 10 to 25 mg of the meglumine.
[0018] In addition, the core portion may further include an acidic stabilizer of an organic acid.
[0019] At this time, the core portion may include 0.4 to 0.6 parts by weight of the organic acid based on 100 parts by weight of the metformin, its pharmaceutically acceptable salt, or their hydrate.
[0020] In addition, the pH of the solution in which the above-mentioned core part is dissolved in purified water may be 6.0 or lower.
[0021] In addition, the organic acid may be one or more selected from the group consisting of fumaric acid, malic acid, citric acid, lactic acid, tartaric acid, and succinic acid.
[0022] Meanwhile, the drug coating layer may comprise 200 to 1,000 parts by weight of meglumine with respect to 100 parts by weight of the linagliptin, its pharmaceutically acceptable salt, or their hydrate.
[0023] In addition, the inner coating layer may be 2 to 6 weight percent of the total weight of the pharmaceutical composite.
[0024] In addition, the composition for the drug coating layer that forms the above drug coating layer may include purified water or isopropanol as a solvent.
[0025] Meanwhile, the pharmaceutical complex formulation according to the present invention may further include an outer coating layer formed on the drug coating layer.
[0026] In addition, the above pharmaceutical combination preparation may be suitable for oral administration.
[0027] In addition, the above pharmaceutical combination preparation may be for the treatment or prevention of diabetes. Effects of the invention
[0028] A pharmaceutical complex formulation according to one embodiment of the present invention has excellent stability of the drug coating layer by including meglumine, a sugar alcohol having an amine group, as a basic stabilizer in the drug coating layer containing linagliptin, and providing an inner coating layer between the core part containing metformin and the drug coating layer.
[0029] In addition, the pharmaceutical complex formulation according to one embodiment of the present invention has excellent N-nitrosodimethylamine (NDMA) stability because an acidic stabilizer of an organic acid is included in the core portion containing metformin to form a low pH environment. Brief explanation of the drawing
[0030] Figure 1 is a graph showing the results of analyzing the linagliptin derivatives in the stability tests of Examples 1 to 3 and Comparative Examples 1 to 3. FIG. 2 is a graph showing the results of analyzing the linagliptin derivatives in the stability tests of Example 1, Examples 4 to 6 and Comparative Examples 4 to 6. Specific details for implementing the invention
[0031] Hereinafter, embodiments of the present invention will be described in detail with reference to the attached drawings. However, these embodiments are intended to illustrate the present invention and the scope of the present invention is not limited by these embodiments. Furthermore, terms not specifically defined in this specification should be understood to have the meanings commonly used in the technical field to which the present invention belongs.
[0033] The present invention relates to a pharmaceutical compound formulation comprising: a core portion comprising metformin, a pharmaceutically acceptable salt thereof, or a hydrate thereof; an endothelial coating layer formed on the core portion; and a drug coating layer formed on the endothelial coating layer comprising linagliptin, a pharmaceutically acceptable salt thereof, or a hydrate thereof, and meglumine.
[0034] Conventionally, when manufacturing a combination product containing two active ingredients, linagliptin and metformin, there was a problem of reduced stability of the combination product because linagliptin reacts with metformin to form a related substance.
[0035] However, the pharmaceutical complex formulation according to one embodiment of the present invention has excellent stability of the drug coating layer by including meglumine, a sugar alcohol having an amine group, as a basic stabilizer in the drug coating layer containing linagliptin, and providing an inner coating layer between the core part containing metformin and the drug coating layer.
[0036] The above core portion may include one or more excipients selected from diluents, binders, lubricants, and sustained-release carriers.
[0037] The above diluent may be selected from the group consisting of, for example, D-mannitol, pregelatinized starch, low-substituted hydroxypropylcellulose (L-HPC), microcrystalline cellulose, sucrose, sorbitol, xylitol, glucose, and mixtures thereof, but is not limited thereto.
[0038] The above binder may be selected from the group consisting of, for example, sodium carboxymethylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, gelatin, povidone, and mixtures thereof, but is not limited thereto.
[0039] The above lubricant may be selected from the group consisting of colloidal silicon dioxide (fumed silica, Aerosil), glyceryl monostearate, glyceryl palmitostearate, calcium stearate, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid, hydrogenated vegetable oil, polyethylene glycol, sodium benzoate, talc, and mixtures thereof, but is not limited thereto.
[0040] The sustained-release carrier may be selected from the group consisting of, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, polyethylene oxide, guar gum, locust bean gum, xanthan gum, glyceryl distearate, sodium carboxymethylcellulose, polyvinylpyrrolidone, and any combination thereof. In one embodiment, the sustained-release carrier may be a combination of hydroxypropylmethylcellulose (HPMC 2280), hydroxypropylmethylcellulose (HPMC 2910), and locust bean gum. The sustained-release carrier may be contained in an amount of 10 to 50 parts by weight, more specifically about 20 to 40 parts by weight, per 100 parts by weight of metformin, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
[0041] In addition, the above drug coating layer may further include excipients such as binders.
[0042] As the above binder, for example, polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), copovidone, macrogol, talc, hard anhydrous silica, synthetic aluminum silicate, calcium silicate, magnesium metasilicate aluminate, calcium hydrogen phosphate, sucrose, gelatin, acacia gum, or a combination thereof may be used.
[0043] Meanwhile, the core portion may contain 500 to 1,000 mg of the metformin, a pharmaceutically acceptable salt thereof, or a hydrate thereof, and the drug coating layer may contain 2.5 to 5.0 mg of the linagliptin, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
[0044] The amounts of the above metformin and linagliptin may be determined based on the number of times administered per day, taking into account each patient's current treatment regimen, efficacy, tolerability, etc.
[0045] In the above pharmaceutical combination formulation, the content of meglumine can be adjusted according to the content of linagliptin, and the amount of meglumine may be 200 to 1,000 parts by weight per 100 parts by weight of linagliptin, its pharmaceutically acceptable salt, or their hydrate. More specifically, when the drug coating layer contains 2.5 to 5.0 mg of linagliptin, its pharmaceutically acceptable salt, or their hydrate, the amount of meglumine may be 10 to 25 mg. If the content of meglumine is lower than the above range, it is difficult to expect the effect of adding meglumine, and the content of impurities may increase rapidly; if the content of meglumine is higher than the above range, the stability of linagliptin may be ensured, but it may become a problem as it exceeds the maximum daily usage limit of meglumine excipient.
[0046] The pharmaceutical complex formulation of the present invention may further include, as a basic stabilizer, one or more selected from the group consisting of precipitated calcium carbonate, L-arginine, sodium bicarbonate (NaHCO3), magnesium carbonate (MgCO3), and magnesium oxide (Mg oxide), in addition to the meglumine of the sugar alcohols having amine groups, but is not limited thereto.
[0047] Meanwhile, the above-mentioned core part may further include an acidic stabilizer of an organic acid.
[0048] In the case of metformin included in the core part above, there is a problem in that the reaction rate increases as the pH environment becomes higher, forming a genotoxic substance harmful to the human body called N-nitrosodimethylamine (NDMA), which is one of the nitrosamines. According to the present invention, an acidic stabilizer of an organic acid is included in the core part containing metformin so that a low pH environment can be formed, thereby providing excellent stability against NDMA.
[0049] Here, the core portion may contain 0.3 to 0.7 parts by weight, preferably 0.4 to 0.6 parts by weight, of the organic acid based on 100 parts by weight of the metformin, its pharmaceutically acceptable salt, or their hydrate. If the content of the organic acid is less than the above numerical range, the pH of the solution in which the core portion of the pharmaceutical complex preparation is dissolved in purified water after being left under harsh conditions (e.g., at a high temperature of about 60°C for 4 weeks or more) exceeds 6.0, and thus the stability against NDMA is not improved; if it exceeds the above numerical range, it is uneconomical and therefore undesirable.
[0050] At this time, the organic acid may be one or more selected from the group consisting of fumaric acid, malic acid, citric acid, lactic acid, tartaric acid, and succinic acid, but is not limited thereto.
[0051] Meanwhile, the inner coating layer may be 2 to 6 weight percent of the total weight of the pharmaceutical complex formulation. If the content of the inner coating layer is less than the above numerical range, it is difficult to expect the effect of the inner coating layer, and the content of the impurity may increase rapidly; if it exceeds the above numerical range, although the stability of linagliptin may be ensured, it is undesirable because it is uneconomical in terms of production, such as increasing the processing time.
[0052] And, the inner coating layer may include any one selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, cellulose acetate phthalate, ethylcellulose, methylcellulose, polymethacrylate, polyethylene glycol, talc, titanium dioxide, and mixtures thereof.
[0053] In addition, the composition for the drug coating layer that forms the above drug coating layer may include purified water or isopropanol as a solvent, but is not limited thereto.
[0054] Meanwhile, the pharmaceutical composite formulation according to the present invention may further include an outer coating layer formed on the drug coating layer. In this case, the coating agent forming the outer coating layer may be one or more polymers selected from the group consisting of a hypromellose-containing coating agent (e.g., Opadry I), a polyvinyl alcohol-containing coating agent (e.g., Opadry II), hypromellose, and hydroxypropylcellulose, but is not limited thereto.
[0055] The pharmaceutical complex formulation described above may be supplemented with pharmaceutically acceptable excipients or carriers, and said excipients or carriers are not particularly limited as long as they are substances commonly used in the relevant art. The said pharmaceutically acceptable excipients may be selected from the group consisting of, for example, sugars, flavorings, sweeteners, acidifiers, preservatives, and any combination thereof. The pharmaceutical complex formulation according to the present invention may be suitable for oral administration and may increase patient compliance with medication.
[0056] The pharmaceutical complex formulation of the present invention may be selected from sustained-release or immediate-release. Sustained-release means that the release of the active ingredient occurs slowly by including a base used for sustained-release purposes in addition to the active ingredient, while immediate-release means that the active ingredient is released immediately.
[0057] In addition, the pharmaceutical complex formulation according to the present invention can be used for the treatment or prevention of diabetes.
[0059] Hereinafter, the present invention will be described in detail based on the following examples. However, the following examples are merely illustrative of the present invention and the scope of the present invention is not limited thereto.
[0061] Examples
[0062] A pharmaceutical combination formulation containing linagliptin and metformin as active ingredients was prepared according to the compositions described in Table 1 (Examples 1 to 3) and Table 2 (Comparative Examples 1 to 3) below.
[0063] Specifically, metformin hydrochloride was mixed with hydroxypropylmethylcellulose (HPMC 2280), hydroxypropylmethylcellulose (HPMC 2910), and locust bean gum using a high-shear granulator (SM-5C, Sejong Pharmatech), then purified water was added as a binder to bind the mixture, and finally sieved through a 20-mesh screen to produce primary wet granules. Colloidal silicon dioxide was subsequently mixed into the prepared primary granules, and magnesium stearate was finally mixed to produce granules. The prepared final granules were compressed into tablets with a hardness of 18–25 kp using a rotary tablet press (GRC-18, Sejong Pharmatech), and sustained-release tablets containing 1,000 mg of metformin hydrochloride were produced.
[0064] A tablet with an inner coating layer formed thereon was prepared by using a coating machine (SFC-30F, Sejong Pharmatech, Korea) on the above-mentioned tablet, in a coating solution mixed with hydroxypropylmethylcellulose (HPMC 2910), hydroxypropylcellulose, talc, and titanium oxide.
[0065] A tablet with a drug coating layer formed thereon was prepared by using a coating machine (SFC-30F, Sejong Pharmatech, Korea) with a coating solution containing linagliptin and meglumine, mixed with hydroxypropylmethylcellulose (HPMC 2910), macrogol 6000, and talc.
[0066] Finally, on the tablet formed with the above drug coating layer, an outer coating layer was formed using Opadry I coating solution as a pharmaceutical immediate-release film coating agent commonly used in the relevant technical field, so that it was about 2.5% by weight based on the total weight of the pharmaceutical complex formulation.
[0067] In the following examples and comparative examples, the weight ratio of excipients was set based on the total weight of the tablets.
[0068] Process Ingredients Example 1 Example 2 Example 3 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.3 1000.0 74.3 1000.0 74.3 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.1 270.0 20.1 270.0 20.1 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1346.0 100.0 1346.0 100.0 1346.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 10.0 38.5 10.0 38.5 10.0 38.5 hydroxypropyl cellulose 10.0 38.5 10.0 38.5 10.0 38.5 Talc 3.0 11.5 3.0 11.5 3.0 11.5 titanium oxide 3.0 11.5 3.0 11.5 3.0 11.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 26.0 100.0 26.0 100.0 26.0 100.0 Drug coating Linagliptin 5.0 6.7 5.0 6.1 5.0 5.6 Meglumine 10.0 13.3 17.5 21.2 25.0 27.8 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 53.3 40.0 48.5 40.0 44.4 Macrogol 6000 10.0 13.3 10.0 12.1 10.0 11.1 Talc 10.0 13.3 10.0 12.1 10.0 11.1 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 75.0 100.0 82.5 100.0 90.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1481.0 - 1488.5 - 1496.0 -
[0069] Process Ingredients Comparative Example 1 Comparative Example 2 Comparative Example 3 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.3 1000.0 74.3 1000.0 74.3 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.1 270.0 20.1 270.0 20.1 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1346.0 100.0 1346.0 100.0 1346.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 10.0 38.5 10.0 38.5 10.0 38.5 hydroxypropyl cellulose 10.0 38.5 10.0 38.5 10.0 38.5 Talc 3.0 11.5 3.0 11.5 3.0 11.5 titanium oxide 3.0 11.5 3.0 11.5 3.0 11.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 26.0 100.0 26.0 100.0 26.0 100.0 Drug coating Linagliptin 5.0 7.7 5.0 7.1 5.0 5.3 Meglumine 0.0 0.0 5.0 7.1 30.0 31.6 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 61.5 40.0 57.1 40.0 42.1 Macrogol 6000 10.0 15.4 10.0 14.3 10.0 10.5 Talc 10.0 15.4 10.0 14.3 10.0 10.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 65.0 100.0 70.0 100.0 95.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1471.0 - 1476.0 - 1501.0 -
[0070] Test Example 1: Linagliptin Impurity Test (Observation of changes according to meglumine amount)
[0071] Under the analysis conditions of the linagliptin filaments of Examples 1 to 3 and Comparative Examples 1 to 3, the linagliptin filaments were measured under harsh conditions as shown in Table 3 below, and the results are shown in Figure 1.
[0072] detector UV absorption spectrophotometer (measurement wavelength: 225 nm) Column YMC Pack Pro C8 (50 x 4.6 mm, 5 μm) or equivalent column column temperature 50 ℃ flux 1.0 mL / min Mobile phase A - Dissolve 2.6 g of ammonium dihydrogen phosphate in water to make 1,000 mL and adjust the pH to 3.0 with phosphoric acid. B - Methanol : Acetonitrile (1 : 1) Hours (minutes) Mobile phase A Mobile phase B 0.0 80 20 10.0 50 50 20.0 30 70 20.1 80 20 25.0 80 20 diluent Mobile phase A : Methanol (1 : 1) Analysis time 25 minutes Injection volume 10 μL of test solution and standard solution
[0073] As shown in FIG. 1, when comparing the total impurity (%) under harsh conditions of Examples 1 to 3 and Comparative Examples 1 to 3, in the case of Examples 1 to 3, the total impurity decreased significantly as the amount of meglumine as a stabilizer for linagliptin increased. When meglumine was absent (Comparative Example 1) or contained a small amount (5 mg) (Comparative Example 2), the impurity increased rapidly as the storage period under harsh conditions lengthened. In the case of Comparative Example 3, although the stability of linagliptin was secured, it did not show a significant difference compared to Example 3, and it is undesirable as it exceeded the maximum daily usage of meglumine excipient. Overall, improved stability of linagliptin can be expected by using meglumine, and sufficient stability effects due to meglumine can be expected not only in drug-coated formulations but also in conventional bilayer tablet combination formulations containing linagliptin and metformin hydrochloride.
[0075] Examples
[0076] Pharmaceutical combination preparations containing linagliptin and metformin as active ingredients were prepared according to the compositions described in Table 4 (Examples 4 to 6) and Table 5 (Comparative Examples 4 to 6) below. The specific method is the same as the method described in the aforementioned examples.
[0077] Process Ingredients Example 4 Example 5 Example 6 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.3 1000.0 74.3 1000.0 74.3 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.1 270.0 20.1 270.0 20.1 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1346.0 100.0 1346.0 100.0 1346.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 15.0 37.5 20.0 38.5 30.0 37.5 hydroxypropyl cellulose 15.0 37.5 20.0 38.5 30.0 37.5 Talc 5.0 12.5 6.0 11.5 10.0 12.5 titanium oxide 5.0 12.5 6.0 11.5 10.0 12.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 40.0 100.0 52.0 100.0 80.0 100.0 Drug coating Linagliptin 5.0 6.7 5.0 6.7 5.0 6.7 Meglumine 10.0 13.3 10.0 13.3 10.0 13.3 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 53.3 40.0 53.3 40.0 53.3 Macrogol 6000 10.0 13.3 10.0 13.3 10.0 13.3 Talc 10.0 13.3 10.0 13.3 10.0 13.3 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 75.0 100.0 75.0 100.0 75.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1495.0 - 1507.5 - 1535.0 -
[0078] Process Ingredients Comparative Example 4 Comparative Example 5 Comparative Example 6 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.3 1000.0 74.3 1000.0 74.3 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.1 270.0 20.1 270.0 20.1 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1346.0 100.0 1346.0 100.0 1346.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 0.0 0.0 5.0 38.5 40.0 36.4 hydroxypropyl cellulose 0.0 0.0 5.0 38.5 40.0 36.4 Talc 0.0 0.0 1.5 11.5 15.0 13.6 titanium oxide 0.0 0.0 1.5 11.5 15.0 13.6 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 0.0 0.0 13.0 100.0 110.0 100.0 Drug coating Linagliptin 5.0 6.7 5.0 6.7 5.0 6.7 Meglumine 10.0 13.3 10.0 13.3 10.0 13.3 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 53.3 40.0 53.3 40.0 53.3 Macrogol 6000 10.0 13.3 10.0 13.3 10.0 13.3 Talc 10.0 13.3 10.0 13.3 10.0 13.3 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 75.0 100.0 75.0 100.0 75.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1455.0 - 1468.0 - 1565.0 -
[0079] Test Example 2: Linagliptin Flexibility Test (Observation of changes according to the amount of inner coating)
[0080] Under the analysis conditions according to Test Example 1, the linagliptin flexible substances of Example 1, Examples 4 to 6 and Comparative Examples 4 to 6 were measured under harsh conditions, and the results are shown in FIG. 2.
[0081] As shown in FIG. 2, when comparing the total impurity (%) under harsh conditions of Examples 1, 4 to 6 and Comparative Examples 4 to 6, in the case of Examples 4 to 6, the total impurity was significantly reduced as the proportion of the inner coating layer, which is intended to block the reaction of impurities between linagliptin and metformin, increased. This demonstrates the effect of blocking impurities generated by the reaction between the amine groups structurally possessed by linagliptin and metformin hydrochloride. When the inner coating layer was absent (Comparative Example 4) or in a small amount of less than 1 weight% relative to the tablet (Comparative Example 5), the impurity increased rapidly as the storage period under harsh conditions lengthened. In the case of Comparative Example 6, although the stability of linagliptin was ensured, it did not show a significant difference from Example 6, and a higher proportion of the inner coating layer increases processing time, which is undesirable from a production perspective. Overall, if the ratio of the endodermal coating layer satisfies 2 to 6 weight percent relative to the total weight of the pharmaceutical combination, improved stability of linagliptin can be expected.
[0083] Examples
[0084] Pharmaceutical combination preparations containing linagliptin and metformin as active ingredients were prepared according to the compositions described in Table 6 (Examples 7 to 9), Table 7 (Examples 10 to 12), Table 8 (Examples 13 to 15), Table 9 (Examples 16 to 18), Table 10 (Comparative Examples 7 to 9), Table 11 (Comparative Examples 10 to 12), Table 12 (Comparative Examples 13 to 15), and Table 13 (Comparative Examples 16 to 18) below. The specific method is the same as the method described in the aforementioned examples.
[0085] Process Ingredients Example 7 Example 8 Example 9 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.1 1000.0 74.1 1000.0 74.1 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.0 270.0 20.0 270.0 20.0 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 fumaric acid 4.0 0.3 - - - - Malsan - - 4.0 0.3 - - citric acid - - - - 4.0 0.3 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1350.0 100.0 1350.0 100.0 1350.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 10.0 38.5 10.0 38.5 10.0 38.5 hydroxypropyl cellulose 10.0 38.5 10.0 38.5 10.0 38.5 Talc 3.0 11.5 3.0 11.5 3.0 11.5 titanium oxide 3.0 11.5 3.0 11.5 3.0 11.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 26.0 100.0 26.0 100.0 26.0 100.0 Drug coating Linagliptin 5.0 5.6 5.0 5.6 5.0 5.6 Meglumine 25.0 27.8 25.0 27.8 25.0 27.8 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 44.4 40.0 44.4 40.0 44.4 Macrogol 6000 10.0 11.1 10.0 11.1 10.0 11.1 Talc 10.0 11.1 10.0 11.1 10.0 11.1 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 90.0 100.0 90.0 100.0 90.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1500.0 - 1500.0 - 1500.0 -
[0086] Process Ingredients Example 10 Example 11 Example 12 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.0 1000.0 74.0 1000.0 74.0 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.0 270.0 20.0 270.0 20.0 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 fumaric acid 6.0 0.4 - - - - Malsan - - 6.0 0.4 - - citric acid - - - - 6.0 0.4 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1352.0 100.0 1352.0 100.0 1352.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 10.0 38.5 10.0 38.5 10.0 38.5 hydroxypropyl cellulose 10.0 38.5 10.0 38.5 10.0 38.5 Talc 3.0 11.5 3.0 11.5 3.0 11.5 titanium oxide 3.0 11.5 3.0 11.5 3.0 11.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 26.0 100.0 26.0 100.0 26.0 100.0 Drug coating Linagliptin 5.0 5.6 5.0 5.6 5.0 5.6 Meglumin 25.0 27.8 25.0 27.8 25.0 27.8 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 44.4 40.0 44.4 40.0 44.4 Macrogol 6000 10.0 11.1 10.0 11.1 10.0 11.1 Talc 10.0 11.1 10.0 11.1 10.0 11.1 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 90.0 100.0 90.0 100.0 90.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1502.0 - 1502.0 - 1502.0 -
[0087] Process Ingredients Example 13 Example 14 Example 15 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.1 1000.0 74.1 1000.0 74.1 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.0 270.0 20.0 270.0 20.0 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 Lactic acid 4.0 0.3 - - - - tartaric acid - - 4.0 0.3 - - Succinic acid - - - - 4.0 0.3 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1350.0 100.0 1350.0 100.0 1350.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 10.0 38.5 10.0 38.5 10.0 38.5 hydroxypropyl cellulose 10.0 38.5 10.0 38.5 10.0 38.5 Talc 3.0 11.5 3.0 11.5 3.0 11.5 titanium oxide 3.0 11.5 3.0 11.5 3.0 11.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 26.0 100.0 26.0 100.0 26.0 100.0 Drug coating Linagliptin 5.0 5.6 5.0 5.6 5.0 5.6 Meglumine 25.0 27.8 25.0 27.8 25.0 27.8 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 44.4 40.0 44.4 40.0 44.4 Macrogol 6000 10.0 11.1 10.0 11.1 10.0 11.1 Talc 10.0 11.1 10.0 11.1 10.0 11.1 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 90.0 100.0 90.0 100.0 90.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1500.0 - 1500.0 - 1500.0 -
[0088] Process Ingredients Example 16 Example 17 Example 18 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.0 1000.0 74.0 1000.0 74.0 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.0 270.0 20.0 270.0 20.0 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 Lactic acid 6.0 0.4 - - - - tartaric acid - - 6.0 0.4 - - Succinic acid - - - - 6.0 0.4 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1352.0 100.0 1352.0 100.0 1352.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 10.0 38.5 10.0 38.5 10.0 38.5 hydroxypropyl cellulose 10.0 38.5 10.0 38.5 10.0 38.5 Talc 3.0 11.5 3.0 11.5 3.0 11.5 titanium oxide 3.0 11.5 3.0 11.5 3.0 11.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 26.0 100.0 26.0 100.0 26.0 100.0 Drug coating Linagliptin 5.0 5.6 5.0 5.6 5.0 5.6 Meglumine 25.0 27.8 25.0 27.8 25.0 27.8 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 44.4 40.0 44.4 40.0 44.4 Macrogol 6000 10.0 11.1 10.0 11.1 10.0 11.1 Talc 10.0 11.1 10.0 11.1 10.0 11.1 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 90.0 100.0 90.0 100.0 90.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1502.0 - 1502.0 - 1502.0 -
[0089] Process Ingredients Comparative Example 7 Comparative Example 8 Comparative Example 9 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.2 1000.0 74.1 1000.0 74.1 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.0 270.0 20.0 270.0 20.0 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 fumaric acid 1.0 0.1 - - - - Malsan - - 1.0 0.1 - - citric acid - - - - 1.0 0.1 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1347.0 100.0 1347.0 100.0 1347.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 10.0 38.5 10.0 38.5 10.0 38.5 hydroxypropyl cellulose 10.0 38.5 10.0 38.5 10.0 38.5 Talc 3.0 11.5 3.0 11.5 3.0 11.5 titanium oxide 3.0 11.5 3.0 11.5 3.0 11.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 26.0 100.0 26.0 100.0 26.0 100.0 Drug coating Linagliptin 5.0 5.6 5.0 5.6 5.0 5.6 Meglumine 25.0 27.8 25.0 27.8 25.0 27.8 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 44.4 40.0 44.4 40.0 44.4 Macrogol 6000 10.0 11.1 10.0 11.1 10.0 11.1 Talc 10.0 11.1 10.0 11.1 10.0 11.1 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 90.0 100.0 90.0 100.0 90.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1497.0 - 1497.0 - 1497.0 -
[0090] Process Ingredients Comparative Example 10 Comparative Example 11 Comparative Example 12 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.2 1000.0 74.2 1000.0 74.2 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.0 270.0 20.0 270.0 20.0 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 fumaric acid 2.0 0.1 - - - - Malsan - - 2.0 0.1 - - citric acid - - - - 2.0 0.1 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1348.0 100.0 1348.0 100.0 1348.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 10.0 38.5 10.0 38.5 10.0 38.5 hydroxypropyl cellulose 10.0 38.5 10.0 38.5 10.0 38.5 Talc 3.0 11.5 3.0 11.5 3.0 11.5 titanium oxide 3.0 11.5 3.0 11.5 3.0 11.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 26.0 100.0 26.0 100.0 26.0 100.0 Drug coating Linagliptin 5.0 5.6 5.0 5.6 5.0 5.6 Meglumine 25.0 27.8 25.0 27.8 25.0 27.8 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 44.4 40.0 44.4 40.0 44.4 Macrogol 6000 10.0 11.1 10.0 11.1 10.0 11.1 Talc 10.0 11.1 10.0 11.1 10.0 11.1 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 90.0 100.0 90.0 100.0 90.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1498.0 - 1498.0 - 1498.0 -
[0091] Process Ingredients Comparative Example 13 Comparative Example 14 Comparative Example 15 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.2 1000.0 74.1 1000.0 74.1 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.0 270.0 20.0 270.0 20.0 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 Lactic acid 1.0 0.1 - - - - tartaric acid - - 1.0 0.1 - - Succinic acid - - - - 1.0 0.1 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1347.0 100.0 1347.0 100.0 1347.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 10.0 38.5 10.0 38.5 10.0 38.5 hydroxypropyl cellulose 10.0 38.5 10.0 38.5 10.0 38.5 Talc 3.0 11.5 3.0 11.5 3.0 11.5 titanium oxide 3.0 11.5 3.0 11.5 3.0 11.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 26.0 100.0 26.0 100.0 26.0 100.0 Drug coating Linagliptin 5.0 5.6 5.0 5.6 5.0 5.6 Meglumine 25.0 27.8 25.0 27.8 25.0 27.8 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 44.4 40.0 44.4 40.0 44.4 Macrogol 6000 10.0 11.1 10.0 11.1 10.0 11.1 Talc 10.0 11.1 10.0 11.1 10.0 11.1 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 90.0 100.0 90.0 100.0 90.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1497.0 - 1497.0 - 1497.0 -
[0092] Process Ingredients Comparative Example 16 Comparative Example 17 Comparative Example 18 mg / T % mg / T % mg / T % mix Metformin hydrochloride 1000.0 74.2 1000.0 74.2 1000.0 74.2 Hydroxypropylmethylcellulose (HPMC 2280) 270.0 20.0 270.0 20.0 270.0 20.0 Hydroxypropylmethylcellulose (HPMC 2910) 8.0 0.6 8.0 0.6 8.0 0.6 Locust Bean Sword 40.0 3.0 40.0 3.0 40.0 3.0 Lactic acid 2.0 0.1 - - - - tartaric acid - - 2.0 0.1 - - Succinic acid - - - - 2.0 0.1 Combined solution purified water Appropriate amount - Appropriate amount - Appropriate amount - Post-mixing Colloidal silicon dioxide 14.0 1.0 14.0 1.0 14.0 1.0 Final mixture Magnesium stearate 14.0 1.0 14.0 1.0 14.0 1.0 Subtotal 1348.0 100.0 1348.0 100.0 1348.0 100.0 Inner coating Hydroxypropylmethylcellulose (HPMC 2910) 10.0 38.5 10.0 38.5 10.0 38.5 hydroxypropyl cellulose 10.0 38.5 10.0 38.5 10.0 38.5 Talc 3.0 11.5 3.0 11.5 3.0 11.5 titanium oxide 3.0 11.5 3.0 11.5 3.0 11.5 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 26.0 100.0 26.0 100.0 26.0 100.0 Drug coating Linagliptin 5.0 5.6 5.0 5.6 5.0 5.6 Meglumine 25.0 27.8 25.0 27.8 25.0 27.8 Hydroxypropylmethylcellulose (HPMC 2910) 40.0 44.4 40.0 44.4 40.0 44.4 Macrogol 6000 10.0 11.1 10.0 11.1 10.0 11.1 Talc 10.0 11.1 10.0 11.1 10.0 11.1 purified water Appropriate amount - Appropriate amount - Appropriate amount - Subtotal 90.0 100.0 90.0 100.0 90.0 100.0 outer coating Opadrei 34.0 - 34.0 - 34.0 - purified water Appropriate amount - Appropriate amount - Appropriate amount - Total 1498.0 - 1498.0 - 1498.0 -
[0094] Test Example 3: Measurement of pH of the metformin core
[0095] For the pharmaceutical complex preparations prepared in the examples and comparative examples of Tables 6 to 13 above, the pH of the core portion containing metformin was measured.
[0096] Specifically, for each tablet, the core containing metformin was taken, ground well to obtain one tablet's worth, added to 50 ml of purified water, and dissolved sufficiently using a stirrer. Then, the pH was measured using a pH meter (Seven compact, METTLER TOLEDO), and the results are shown in Tables 14 to 17 below.
[0098] Test Example 4: Measurement of NDMA in Pharmaceutical Combination Preparations
[0099] The NDMA content of the composite formulations prepared in Examples 7 to 18 and Comparative Examples 7 to 18 was measured.
[0100] Specifically, for each manufactured example and comparative example, samples were prepared immediately after manufacturing and after being stored at 60°C for 4 weeks.
[0101] The test solutions of the samples were prepared by the following pretreatment method, and the obtained test solutions were analyzed using UPLC-MSMS (TQ-S, Waters). The analysis results were converted into a pharmaceutical composition containing 1000 mg of metformin hydrochloride, and the results are shown in Tables 14 to 17 below.
[0102] The above test solution was prepared by grinding the pharmaceutical composition containing 1000 mg of metformin hydrochloride from the examples and comparative examples, accurately weighing out an amount equivalent to 500 mg of metformin hydrochloride, placing it in a 50 ml Falcon tube, accurately taking 5 ml of 1 mol (mol / L) hydrochloric acid and 50 μl of internal standard solution (1 μg / ml), and mixing by shaking thoroughly. Then, accurately adding 5 ml of dichloromethane to this solution and mixing by shaking thoroughly, followed by centrifugation at 4,000 rpm for 10 minutes. An appropriate amount of the dichloromethane layer was carefully taken and filtered through a 0.22 μm membrane filter (PTFE); the first filtrate was discarded, and the subsequent filtrate was used as the test solution.
[0103] The above internal standard solution was prepared by accurately weighing 1.0 ml of the internal standard substance NDMA-d6 (1,000 μg / ml), adding methanol to make it exactly 50 ml, and using it as the internal standard stock solution (20 μg / ml). 500 μl of this solution was accurately weighed, added methanol to make it exactly 10 ml, and used as the internal standard solution (1 μg / ml).
[0104] 40 μl of NDMA standard solution (5,000 μg / ml) was accurately weighed and methanol was added to make it exactly 10 ml to prepare the standard stock solution (20 μg / ml). 500 μl of this solution was accurately weighed and methanol was added to make it exactly 10 ml to prepare the standard solution (1 μg / ml). The above standard solution and internal standard solution (IS) were each weighed and mixed, and then dichloromethane was added to make it exactly 10 ml to prepare the linearity standard solution.
[0105] In interpreting the experimental data, the method was validated by considering the analytical sensitivity of the LC-MSMS device and the concentration of the analysis sample. Based on the results, the limit of quantification (LOQ) was set to less than 10 ppb, but values below the LOQ were also indicated to confirm the correlation between pH and NDMA.
[0106] Sample name Example 7 Example 8 Example 9 Example 10 Example 11 Example 12 pH 5.7 5.8 5.6 5.2 5.3 5.1 NDMA (Initial) 3.9 ppb 3.8 ppb 3.9 ppb 3.7 ppb 4.2 ppb 4.1 ppb NDMA (harsh 4 weeks) 7.2 ppb 6.3 ppb 6.6 ppb 5.8 ppb 6.5 ppb 7.7 ppb
[0107] Sample name Example 13 Example 14 Example 15 Example 16 Example 17 Example 18 pH 5.4 5.8 5.8 4.9 5.3 5.4 NDMA (Initial) 3.8 ppb 3.7 ppb 4.1 ppb 4.0 ppb 4.1 ppb 3.8 ppb NDMA (harsh 4 weeks) 5.8 ppb 6.3 ppb 6.7 ppb 5.5 ppb 7.5 ppb 7.6 ppb
[0108] Sample name Comparative Example 7 Comparative Example 8 Comparative Example 9 Comparative Example 10 Comparative Example 11 Comparative Example 12 pH 6.5 6.6 6.5 6.2 6.3 6.1 NDMA (Initial) 3.7 ppb 3.9 ppb 3.8 ppb 4.2 ppb 4.1 ppb 4.1 ppb NDMA (harsh 4 weeks) 21.2 ppb 22.6 ppb 18.9 ppb 18.3 ppb 17.7 ppb 17.9 ppb
[0109] Sample name Comparative Example 13 Comparative Example 14 Comparative Example 15 Comparative Example 16 Comparative Example 17 Comparative Example 18 pH 6.4 6.6 6.6 6.1 6.3 6.4 NDMA (Initial) 4.0 ppb 3.8 ppb 3.7 ppb 3.7 ppb 3.9 ppb 4.1 ppb NDMA (harsh 4 weeks) 20.7 ppb 21.9 ppb 22.7 ppb 16.8 ppb 18.5 ppb 18.7 ppb
[0110] N-nitrosodimethylamine (NDMA), one of the nitrosamines, has a reaction rate that increases with higher pH environments, forming genotoxic substances harmful to the human body. The Ministry of Food and Drug Safety’s provisional management standards are set as follows: “Based on the maximum daily allowable dose (96 nanograms), assuming the maximum daily dose is taken for a lifetime, the standard is 0.096 ppm when taking a maximum of 1,000 mg per day, and 0.038 ppm when taking a maximum of 2,550 mg per day.”
[0111] As shown in Tables 14 and 15, in the case of Examples 7 to 18, it can be seen from the pH measurement results of the core part containing metformin that the pH of the product varied depending on the type and amount of acidifying agent used. For example, when organic acids such as fumaric acid, malic acid, citric acid, lactic acid, tartaric acid, and succinic acid were used as acidifying agents, it was possible to adjust the pH of the metformin tablet.
[0112] In addition, although the NDMA concentration in all of the examples met the provisional management standards of the Ministry of Food and Drug Safety immediately after manufacturing and when stored at 60°C for 4 weeks, the present invention can provide a stable pharmaceutical complex formulation that can suppress the amount of NDMA generated without increasing it through the pharmaceutical complex formulation.
[0114] In the case of Examples 7 to 18, when the pH of the core portion containing metformin was 6.0 or lower immediately after preparation and when stored at 60°C for 4 weeks, the NDMA concentration was below the quantification limit (10 ppb), taking into account the analytical sensitivity of the LC-MSMS device and the concentration of the analysis sample. This means that no significant difference was observed.
[0115] In the case of Comparative Examples 7 to 18, when the pH of the core part containing metformin exceeded 6.0 immediately after manufacturing and when stored at 60°C for 4 weeks, the NDMA concentration tended to increase. This indicates that even if it is within the provisional standards of the Ministry of Food and Drug Safety, there is a potential tendency for it to increase sufficiently during storage, which is undesirable as an optimized pharmaceutical combination product.
[0117] The present invention has been described above with reference to its preferred embodiments. Those skilled in the art will understand that the present invention may be embodied in modified forms without departing from the essential characteristics of the invention. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the invention is defined by the claims, not by the foregoing description, and all variations within the scope of the claims should be interpreted as being included in the invention.
Claims
Claim 1 A pharmaceutical complex comprising: a core portion comprising metformin, a pharmaceutically acceptable salt thereof, or a hydrate thereof; an endothelial coating layer formed on the core portion; and a drug coating layer formed on the endothelial coating layer comprising linagliptin, a pharmaceutically acceptable salt thereof, or a hydrate thereof, and meglumine, wherein the pH of a solution in which the core portion is dissolved in purified water is 6.0 or lower, the endothelial coating layer is 2 to 6 weight% with respect to the total weight of the pharmaceutical complex, and the drug coating layer comprises 200 to 1,000 weight parts of meglumine per 100 weight parts of the linagliptin, a pharmaceutically acceptable salt thereof, or a hydrate thereof. Claim 2 A pharmaceutical complex formulation according to claim 1, wherein the core portion comprises 500 to 1,000 mg of the metformin, a pharmaceutically acceptable salt thereof, or a hydrate thereof, and the drug coating layer comprises 2.5 to 5.0 mg of the linagliptin, a pharmaceutically acceptable salt thereof, or a hydrate thereof. Claim 3 In paragraph 2, the drug coating layer is a pharmaceutical complex formulation comprising 10 to 25 mg of the meglumine. Claim 4 In claim 1, the core portion further comprises an acidic stabilizer of an organic acid, forming a pharmaceutical complex formulation. Claim 5 In claim 4, the core portion comprises 0.4 to 0.6 parts by weight of the organic acid based on 100 parts by weight of the metformin, its pharmaceutically acceptable salt, or their hydrate. Claim 6 delete Claim 7 In paragraph 4, the above organic acid is a pharmaceutical complex preparation in which one or more are selected from the group consisting of fumaric acid, malic acid, citric acid, lactic acid, tartaric acid, and succinic acid. Claim 8 delete Claim 9 delete Claim 10 In claim 1, the composition for the drug coating layer that forms the drug coating layer is a pharmaceutical complex formulation comprising purified water or isopropanol as a solvent. Claim 11 In claim 1, the pharmaceutical complex formulation further comprises an outer coating layer formed on the drug coating layer. Claim 12 In paragraph 1, the above pharmaceutical complex is a pharmaceutical complex suitable for oral administration. Claim 13 In paragraph 1, the above pharmaceutical complex is a pharmaceutical complex for the treatment or prevention of diabetes.
Citation Information
Patent Citations
Refining method of metformin hydrochloride
CN110194727A
Oral preparations of biguanide drugs
JP2002512953A
Sustained-release formulation and combinative sustained-release tablet with sustained-release pellets
KR1020060096728A
Sustained release formulations containing metformin orits salt and processes for preparing the same
KR1020080001772A
DPP-IV Inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
KR1020110005690A
